ImmusanT scores a $40M round for PhII celiac study, with biotech vet Tom Daniel joining the board
Celgene vet Tom Daniel’s role as a partner at Arch Venture will take him to the board at Cambridge, MA-based ImmusanT, a biotech startup that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
